Company profile
COMPASS Pathways plc
NASDAQ:CMPSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Psilocybin | phase3 | — | 7 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05733546 | phase2 | active_not_recruiting | 2023-01-30 | 2025-09-01 | COMPASS Pathways | A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder |
| NCT05481736 | phase2 | completed | 2022-10-12 | 2024-11-18 | COMPASS Pathways | Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study |
| NCT05624268 | phase3 | completed | 2023-01-24 | 2025-05-28 | COMPASS Pathways | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
| NCT05711940 | phase3 | active_not_recruiting | 2023-02-14 | 2025-11-13 | COMPASS Pathways | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
| NCT07570654 | phase2_3 | recruiting | 2026-09-01 | 2028-11-01 | COMPASS Pathways | Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder |
FDA applications (0)
No records yet.